A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy

Abstract

Key Points We created the first transgenic mouse model recapitulating the early pathologic features of Randall-type heavy chain deposition disease. Production of a truncated immunoglobulin heavy chain heightens plasma cell sensitivity to bortezomib via a terminal unfolded protein response.